Contineum Therapeutics
CTNM
80 hedge funds and large institutions have $338M invested in Contineum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 29 increasing their positions, 8 reducing their positions, and 11 closing their positions.
263% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 8
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
64% more capital invested
Capital invested by funds: $206M → $338M (+$133M)
47.2% more ownership
Funds ownership: 80.95% → 128.15% (+47%)
29% more funds holding
Funds holding: 62 → 80 (+18)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
27% less call options, than puts
Call options by funds: $117K | Put options by funds: $160K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$27.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$15.3M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$12.8M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.2M |
| 5 |
CC
Commodore Capital
New York
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.69M |
| 2 |
BEAM
Baker Ellis Asset Management
Vancouver,
Washington
|
-$229K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
-$228K |
| 4 |
Squarepoint
New York
|
-$154K |
| 5 |
B
Bailard
Foster City,
California
|
-$145K |
CTNM Hedge Fund Activity: Q4 2025 in Review
80 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q4 2025, worth a combined $338M — up 64% from $206M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CTNM positions and 11 closed out — a net gain of 20 holders — while 29 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $27.9M. The largest seller was Samsara BioCapital, cutting an estimated $5.69M.
- 80 institutional investors held Contineum Therapeutics (CTNM) as of Q4 2025, up from 62 in Q3 2025.
- Funds reported $338M of Contineum Therapeutics stock for Q4 2025, up 64% quarter-over-quarter.
- 31 funds opened new Contineum Therapeutics positions in Q4 2025 and 11 closed out, a net change of +20 holders.
- The largest Contineum Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $27.9M added.
- The largest Contineum Therapeutics seller in Q4 2025 was Samsara BioCapital, an estimated $5.69M sold.
Based on aggregated 13F filings for Q4 2025.